Australia markets close in 54 minutes

Clarus Therapeutics Holdings, Inc. (CRXT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.3155+0.0075 (+2.44%)
At close: 04:00PM EDT
0.3194 +0.00 (+1.24%)
After hours: 07:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3080
Open0.3100
Bid0.0000 x 900
Ask0.0000 x 1000
Day's range0.3000 - 0.3383
52-week range0.2610 - 31.2400
Volume3,443,700
Avg. volume3,596,256
Market cap16.413M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.8000
Earnings date16 May 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.63
  • GlobeNewswire

    Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)

    JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July 28, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a notice of allowance from the U

  • GlobeNewswire

    Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting

    JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., June 09, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for JATENZO (testosterone undecanoate) will be

  • GlobeNewswire

    Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

    JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent in FDA’s Orange Book, which would bring the total number of Orange Book-listed patents covering JATENZO to eight NORTHBROOK, Ill., May 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical ne